Childhood Cancer Initiative Granted $2.5M
News Jul 25, 2016
The UC Santa Cruz Genomics Institute has received a $2.5 million grant over the next five years from St. Baldrick’s Foundation, the largest private funder of childhood cancer research grants. The grant supports the Treehouse Childhood Cancer Initiative, which brings the power of genomics and big-data analytics to bear on the challenge of finding effective treatments for children with cancer.
Genomic analysis of tumor cells can reveal the genetic errors driving an individual patient’s cancer, and doctors can use that information to design targeted therapies. To realize the full potential of cancer genomics, however, the information from an individual patient must be compared against data from a large number of other cases. This is problematic for childhood cancers, which are relatively rare, making it difficult to assemble large cohorts to study.
The Treehouse Initiative was established to enable the sharing of pediatric cancer data so that each patient’s data can be analyzed in the context of large datasets of both pediatric and adult cancers.
“Genomic medicine requires massive data sharing and analysis, and that is the emphasis of the Treehouse Initiative,” said David Haussler, professor of biomolecular engineering and scientific director of the Genomics Institute at UC Santa Cruz. “It is only by sharing data that we can deploy genomic insights to their full potential in pediatric cancer and other diseases.”
With the new funding from St. Baldrick’s, UC Santa Cruz will work with six clinical partners that have agreed to share and jointly analyze data from pediatric patients enrolled in genomic medicine clinical trials: Children’s Hospital of Orange County; Stanford University; Pacific Pediatric NeuroOncology Consortium; the Pediatric Personalized Oncogenomics Program of British Columbia; Peds Mi-OncoSeq Program at the University of Michigan Cancer Center; and Molecular Guided Therapy in Neuroblastoma at Children’s Hospital of Philadelphia.
The Treehouse Initiative will perform a massive comparison of each child’s cancer data and cross-reference it with more than 10,000 tumors from previous genomics projects. This huge comparison, known as pan-cancer analysis, uses big data to reveal how genomic aberrations drive cancer. The Treehouse Initiative’s comparative approach enables researchers to find hidden causes of cancer in individual patients, including targetable drivers of the cancer that may be missed when analyzing each patient’s data in isolation. This approach can suggest new precision treatments for patients whose cancer has not responded to standard therapies.
Through this new effort over the next five years funded by St. Baldrick’s, the Treehouse Childhood Cancer Initiative will aim to at least double the number of pediatric patients whose cancers are treated based on insights derived from genomic sequencing. The UC Santa Cruz Genomics Institute has long been a leader in open-source, big-data genomics, and the Treehouse Initiative is bringing a new level of real-time data sharing and analysis to pediatric cancer genomics.
A Treehouse pilot project, the California Kids Cancer Comparison Initiative, has already shown that this approach can benefit children with cancer. “Our analysis has revealed new therapeutic options for patients being treated in the clinic today. By looking at each child in the context of tens of thousands of other cases, we are demonstrating the clinical utility of data sharing and cross-tumor comparisons,” said Treehouse cofounder Olena Morozova, a research scientist at the Genomics Institute.
By sharing data, the Treehouse Initiative allows each patient to immediately benefit from what is learned in other cases. Families are eager to participate, Haussler said. Pediatric cancer is a struggle for every family it touches, and the Treehouse Initiative will work to turn these struggles into meaningful clinical insights that will help everyone faced with childhood cancer.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.